• Myeloma UK
  • Clinical Service Excellence Programme
Myeloma Academy
Sign inRegister
Menu
  • Home
  • CPD & Learning
    • Myeloma Nurse Learning Programme
    • My CPD Portfolio
    • Challenging Cases
    • Close
  • Library
    • Guidelines
      • Complications
      • COVID-19 guidance
      • General haemato/oncology
      • Imaging & Analysis
      • Management & Treatment
      • Palliative Care
      • Presentation & Diagnosis
      • Related conditions
      • Close
    • Patient Support and Information
    • Medical animations
    • Remote consultation video
    • Close
  • Resources
    • Myeloma Drug Finder
    • Myeloma Trial Finder
    • Assessment tools
    • Myeloma Spotlight
    • Primary care education
    • Secondary care education
    • Myeloma Nurse Guides
    • Myeloma health economic model
    • Laboratory Practice
    • Close
  • News & Events
    • News
    • Event calendar
    • Meeting highlights
    • Close
  • CSEP
  • About Us
    • Contact Us
    • Close
Menu back  
 

Related conditions

Diffuse Parenchymal Pulmonary Amyloidosis Showing an Objective Response to Bortezomib-based Chemotherapy.
Higo H et al. Intern Med. 2014;53(16):1809-12. Epub 2014 Aug 15.

Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias.
Kourelis TV et al. Am J Hematol. 2014 Aug 11. doi: 10.1002/ajh.23827. [Epub ahead of print].

Immunophenotypic analysis of abnormal plasma cell clones in bone marrow of primary systemic light chain amyloidosis patients.
Hu Y et al. Chin Med J (Engl). 2014 Aug;127(15):2765-70.

  • Guidelines
  • Patient Support and Information
  • Medical animations
  • Remote consultation video
Bottom menu

Charity No. SC 026116
Myeloma UK
22 Logie Mill
Beaverbank Business Park
Edinburgh
EH7 4HG